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Ceftolozane, formally CXA-101, is a new antipseudomonal cephalosporin that is also active in vitro against Enterobacteriaceae
but is vulnerable to extended-spectrum -lactamases (ESBLs). The addition of tazobactam is intended to broaden coverage to
most ESBL-producing Escherichia coli and Klebsiella pneumonia as well as other Enterobacteriaceae. The in vitro activities of
ceftolozane-tazobactam combinations against 67 clinically andmolecularly characterized ESBL-producing isolates were exam-
ined by checkerboardMIC testing to evaluate their potential clinical feasibility and to assess the optimal tazobactam concentra-
tions to be used in MIC determinations of ceftolozane. Isolates included those from E. coli (n 32), K. pneumoniae (n 19),
Enterobacter cloacae (n 15), and Citrobacter freundii (n 1). Checkerboard experiments were performed to study interac-
tions over the range of 0.008 to 64 mg/liter ceftolozane and 0.063 to 32 mg/liter tazobactam using 2-fold-dilution series. The
MIC50 andMIC90 of ceftolozane alone for all isolates were 16 and>64 mg/liter, respectively. Increasing concentrations of tazo-
bactam resulted in decreasingMICs of ceftolozane. The 50th and 90th percentile concentrations of tazobactam required to re-
duce theMIC of ceftolozane to 8 mg/liter for all organisms in this ESBL collection were 0.5 and 4mg/liter, respectively. For E.
coli, K. pneumoniae, and E. cloacae, these values were 0.5 and 2, 1 and 16, and 0.5 and 4 mg/liter, respectively. When combined
with a fixed amount of 4 mg/liter tazobactam (current CLSI concentration used for susceptibility testing), 90% of the isolates
would have anMIC of<4 mg/liter. The combination ceftolozane-tazobactam is a promising alternative option for treating infec-
tions due to ESBL-harboring isolates.
The global spread of extended-spectrum -lactamases (ESBLs)has been an ongoing problem since the first report appeared in
1983 (1–3).Many 3rd- and 4th-generation cephalosporins are less
effective in treating infections caused by these ESBL-producing
isolates (4, 5). The development of new antibiotics has always
played a key role in providing a solution to the emergence of these
resistant mechanisms (6, 7). The new cephalosporin ceftolozane
(CXA-101; Cubist Pharmaceuticals, Inc.) is a promising agent that
possesses activity against Pseudomonas spp. and certain members
of the Enterobacteriaceae family, but unfortunately the compound
is still vulnerable to many ESBLs (8).
Another approach to overcome resistance due to -lactamases
is to use a -lactamase inhibitor in combination with a -lactam
antibiotic to extend its spectrum of activity. Currently available
-lactamase inhibitors include tazobactam, clavulanic acid, and
sulbactam, and some bacteria grouped into Ambler class A and
Class C may be inhibited by them (5, 9). Existing drug combina-
tions such as piperacillin-tazobactam and amoxicillin-clavulanic
acid are still among the most successfully used antibiotics (10).
Some in vitro studies (11–13) have previously indicated that
combining ceftolozane with a -lactamase inhibitor such as tazo-
bactam might overcome its vulnerability to ESBLs. However, the
optimal concentration of tazobactam to use in susceptibility test-
ing is unclear, and the concentration-effect relationship against
these isolates has yet to be established. Therefore, we set out to
determine the inhibition of ESBL-producing isolates by ceftolo-
zane and tazobactam using the checkerboard technique to exam-
ine the optimum concentration of tazobactam to enhance the
MICs of ceftolozane.
MATERIALS AND METHODS
Bacterial isolates. We used 67 phenotypically and genotypically con-
firmed ESBL-producing isolates of Enterobacteriaceae that had been col-
lected during a prevalence study.Details are described elsewhere (14). The
isolates included 32 Escherichia coli, 19 Klebsiella pneumoniae, 15 Entero-
bacter cloacae, and 1 Citrobacter freundii. In brief, initial screening for
ESBL was done on BLSE agar biplates (AES Chemunex, Bruz Cedex,
France). Presumptive ESBLs were confirmed by Etest TZ/TZL and CT/
CTL strips (AB Biodisk, Solna, Sweden) and, if necessary, the PM/PML
strip. The modified Hodge test (MHT) was used to detect carbapenemase
production when the MIC of meropenem was0.125 mg/liter. PCR ex-
periments were performed to detect blaTEM, blaSHV, blaOXA, and blaCTX-M
genes. A summary of the -lactamase characteristics of these isolates is
shown in Table 1.
Nine extra isolates producing K. pneumoniae carbapenemase (KPC)
or AmpC enzymes, which did not or only poorly inhibited tazobactam
(see the supplementalmaterial), were added to serve as a negative control.
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These included 6 K. pneumoniae isolates and 1 C. freundii isolate harbor-
ing KPC -lactamase and 2 E. coli AmpC producers.
Compounds. Ceftolozane (lot 440420 00010) and tazobactam (lot
9080146JE) were provided as a standard powder by Cubist Pharmaceuti-
cals, Inc. Ceftazidime was purchased commercially as ceftazidime penta-
hydrate (batch no. 18D3368). Stock solutions were prepared according to
the manufacturer’s instructions.
Susceptibility testing.MICs were determined by CLSI- (15) and ISO-
compliant (16) methods for microbroth dilution. Working solutions of
ceftolozane and tazobactam were made in freshly prepared Mueller-Hin-
ton broth (MHB) (Difco batch no. 9106707; Brunschwig chemie, Amster-
dam, Netherlands). Combinations of the two agents were used for the
checkerboard titrations to yield a final range of log2 dilutions of 0.008 to
64 mg/liter ceftolozane and 0.0625 to 32 mg/liter tazobactam, which en-
compassed the CLSI-approved concentration for tazobactam of 4 mg/
liter. Two disposable plastic microdilution trays were used for each deter-
mination with each tray containing a negative and a positive growth
control, with every set of two containing 0.008 to 64 mg/liter ceftolozane
alone and 0.008 to 64 mg/liter ceftazidime as a comparator as well. The
trays were stored at80°C until use. On the day of the experiment, trays
were thawed, inoculated to a final concentration of 0.5  105 CFU/ml,
and incubated at 35°C in ambient air for 18 to 20 h. MICs were read with
MIC being determined by the lowest concentration of the agent that com-
pletely inhibited visible growth. Each set of MIC determinations included
three ATCC strains, E. coli (ATCC 25922), Pseudomonas aeruginosa
(ATCC 27853), and K. pneumoniae (ATCC 700603), as controls.
Analysis. MIC50 and MIC90 values for ceftolozane, alone and com-
bined with tazobactam, were defined as the lowest concentration of the
antibiotic that inhibited 50% and 90% of the isolates of the collection,
respectively.
The effect of tazobactam on the MIC of ceftolozane was expressed in
the number of changes in 2-fold dilutions compared to the MIC of cef-
tolozane alone. The effect of the combination was depicted as the cumu-
lative percentage (%) of isolates inhibited (Excel 2008 for Mac, version
12.3.6). The susceptibility to ceftazidime was interpreted according to
EUCAST criteria (17).
RESULTS
Ceftolozane alone showed a similar overall intrinsic activity
against the 67 Enterobacteriaceae isolates compared to ceftazidime
(see the supplemental material). The overall mean difference in
MICwas 0.164 log2 dilutions, whichwas not significantly different
from0.Overall, theMIC50 andMIC90 of ceftolozane alonewere 16
and 64 mg/liter, respectively. The highest MICs were found
among isolates harboring a CTX-M-15 enzyme with or without
another -lactamase. MICs of 64 mg/liter were found for 90%
of the isolates carrying these genes for encoding CTX-M-15 en-
zymes.
Full ceftolozane-tazobactam checkerboard testing was per-
formed for each isolate for all drug combinations stated. No
change in MIC was observed after the addition of tazobactam for
the isolates harboring KPC enzymes, and there was only a slight
reduction in the MICs for the AmpC-producing isolates at very
high concentrations. These isolates served as a negative control
andwere not taken into accountwhile analyzing the study isolates.
The effects of tazobactam on the MICs of ceftolozane for the
different species are shown in Fig. 1 as a cumulative inhibition in
heat plots and as MIC50 and MIC90 values of ceftolozane for in-
creasing concentrations of tazobactam (Table 2). Each indicates a
concentration-dependent effect of tazobactam on the in vitro ac-
tivity of ceftolozane. As expected, tazobactam alone showed no
effect (18). The magnitude of the decrease in MIC was less for K.
TABLE 1 Isolates for each species with specific -lactamasesa
Enzyme









TEM-1b 14 4 2 1
TEM-12 1
TEM-52 1






SHV-12 1 1 6
SHV-33 1
LENb 1 1





CTX-M-9 3 1 7
CTX-M-14 4
CTX-M-15 16 3 1
CTX-M-39 1 2 1
CTX-M 1
a Of the isolates, 68.7% harbored more than one -lactamase.
b Broad-spectrum -lactamase.
c Inhibitor resistant.
FIG1 Cumulative percentage of inhibition by ceftolozane at increasing tazobactam concentrations for E. coli (left, n 32),K. pneumoniae (middle, n 19), and
E. cloacae (right, n 15) in heat diagrams. Values are milligrams per liter.
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pneumoniae and E. cloacae than for E. coli (Fig. 1, Table 2) indi-
cating that E. coli isolates are more susceptible to lower concen-
trations of tazobactam combined with ceftolozane.
Adding tazobactam at concentrations of 1 to 4 mg/liter had
the most pronounced effect on MICs of ceftolozane against E.
coli (Table 2). In contrast, MIC50 values against K. pneumoniae
showed a reasonable decline inMICs of ceftolozane although high
MIC90 values forK. pneumoniae persisted despite increasing tazo-
bactam concentrations indicating that some isolates are not fully
inhibited. Virtually no effect was observed for K. pneumoniae at
tazobactam concentrations of 1 mg/liter, and at 4 mg/liter the
MICs were still 8 mg/liter for 21% (n  4) of strains. Three of
these isolates harbored SHV-5 enzymes suggesting that the effi-
cacy of the ceftolozane-tazobactam combination also depends on
the type of ESBL.
Tazobactam concentrations of 4 mg/liter did not markedly
lower ceftolozaneMICs further.At afixedconcentrationof4mg/liter
tazobactam, theMIC50 andMIC90 of ceftolozanewere reduced to 0.5
and4mg/liter, respectively.A tazobactamconcentrationof 4mg/liter
resulted in anMIC for ceftolozane of4mg/liter for 90%of the total
number of isolates, and adding more tazobactam did not result in a
further reduction for 20% of the isolates.
At the highest tazobactam concentration tested (32mg/liter), the
median difference in 2-fold dilutions was 7 for E. coli, 6 for K. pneu-
moniae, and 4 for E. cloacae. The distribution of the changes in
number of 2-fold dilutions compared to the initialMICof ceftolo-
zane without tazobactam is shown in Fig. 2 for concentrations of
1, 4, and 8 mg/liter tazobactam. For some isolates, a 10 log2 de-
crease in MIC was observed, and there appears to be a bimodal
distribution at 4 and 8 mg/liter tazobactam. The second subpop-
ulation starting at 7 doubling dilutions consisted of E. coli iso-
lates harboring at least a CTX-M-15 enzyme. MICs of ceftolozane
against other species harboring this enzyme were less responsive
by increasing tazobactam concentrations, indicating that the
overall effect of the inhibitor is dependent on the species and
type of enzyme.







(n 67) E. coli (n 32) K. pneumoniae (n 19) E. cloacae (n 15)
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
0 16 64 32 64 16 64 16 32
0.063 16 64 16 64 16 64 16 32
0.125 16 64 16 64 16 64 16 32
0.25 16 64 16 32 16 64 16 32
0.5 8 64 4 32 16 64 8 32
1 1 16 1 16 4 64 8 16
2 1 16 1 2 4 64 8 16
4 0.5 4 0.25 1 1 32 2 4
8 0.5 4 0.25 1 1 16 1 4
16 0.5 2 0.25 0.5 0.5 2 0.5 4
32 0.25 1 0.125 0.5 0.5 2 0.5 4
FIG 2 Distribution of the effect of tazobactam (TAZ) on the MIC of ceftolozane among all isolates (n 67) expressed as the 2-fold-dilutions decrease in MIC
at 3 different concentrations of tazobactam.
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Our study showed that tazobactam enhanced the potency of cef-
tolozane against ESBL-producing Enterobacteriaceae in a dose-
dependent manner. However, the efficacy of this drug combina-
tionwas also dependent on the species and type of ESBL. Themost
pronounced inhibitory effect was seen for E. coli. Combining cef-
tolozane with 4 mg/liter tazobactam restored 55% of the MICs to
that reported for wild-type (non-ESBL) distributions (8, 19).
The results show that increasing concentrations of tazobactam
results in a decreasedMIC of ceftolozane.With a fixed concentra-
tion of 4mg/liter tazobactam, 90%of the isolates in this collection
would have a combination MIC of4 mg/liter (and an MIC50 of
0.5 mg/liter), which extends the spectrum of activity of ceftolo-
zane, thereby showing potential usefulness for treating infections
due to ESBL-producing isolates. These results differ from those
reported by Farrell et al. (20) and Sader et al. (12, 21) who con-
ducted several large studies in Europe and the United States and
used a collection of Enterobacteriaceae isolates with MIC50 and
MIC90 values of 4 mg/liter and 32 mg/liter, which are higher than
we found in our study. One explanation may be the higher resis-
tance rate to piperacillin-tazobactam, ceftazidime, and mero-
penem in their studies. Unlike in our study, their isolates were
ESBL screen-positive phenotypes based on the CLSI screening cri-
teria for potential ESBL production and were not confirmed by
other tests. Hence, no distinction was made between ESBLs and
other -lactamases such as KPC or AmpC that would also pro-
duce anESBL screen-positive phenotype.Wehadnomeropenem-
resistant isolates in our collection, and the ceftolozane MIC50 was
4mg/liter and theMIC90 was 32mg/liter whenwe recalculated the
data with isolates exhibiting a piperacillin-tazobactam MIC of
16 mg/liter. This is similar to their findings. The same was ob-
served for the ESBLs of E. coli isolates and, to a lesser extent, of K.
pneumoniae isolates because they conferred a higher resistance to
piperacillin-tazobactam and ceftazidime.
The number of isolates for each specific species--lactamase
combinationwas relatively small, andwe cannot exclude the pres-
ence of additional resistant mechanisms or ESBLs that we were
unable to detect. Nevertheless, since our study was representative
of the isolates obtained from a prevalence survey, it provides a
reasonable representation of the in vitro effects of tazobactam on
the MIC of ceftolozane, as there is little or no bias in selecting the
isolates. Moreover, the prevalence of CTX-M-15 concomitant
with a TEM-1 and or an OXA-1 -lactamase was consistent with
observations in other European countries (22–24).
A considerable number of isolates also exhibited multiple
-lactamases, and this is likely to increase over the next several
years (25, 26). The prevalence and distribution of specific
ESBLs is often geographical and, therefore, monitoring trends
in MICs will provide a valuable tool to combat ESBLs (27).
-lactam-inhibitor combinations should also be tested specif-
ically to determine whether shifts in prevalence or harboring
multiple ESBLs have any impact on the MIC distributions. Us-
ing a concentration of 4 mg/liter tazobactam for such combi-
nations in the microdilution assay seems a reasonable choice
although the correlation between in vitro susceptibility test re-
sults and clinical efficacy should be demonstrated in pharma-
codynamic studies in clinical studies.
In conclusion, ceftolozane in combination with 4 mg/liter ta-
zobactam enhanced the overall in vitro activity against most of the
Enterobacteriaceae harboring ESBLs. However, caution should be
used for K. pneumoniae ESBLs, in particular SHV-5 and CTX-M-
15, because high MICs remain despite by increasing tazobactam
concentrations.
ACKNOWLEDGMENTS
This study was performed with an unrestricted grant from Cubist Phar-
maceuticals USA.
J. W. Mouton received research grants from and/or was a consultant
for Merck Inc. USA, Pfizer, Polyphor, Cubist, Astra-Zeneca, Basilea, and
Roche.
REFERENCES
1. Bradford PA. 2001. Extended-spectrum beta-lactamases in the 21st cen-
tury: characterization, epidemiology, and detection of this important re-
sistance threat. ClinMicrobiol Rev 14:933–951. http://dx.doi.org/10.1128
/CMR.14.4.933-951.2001.
2. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. 1983. Transfer-
able resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in
clinical isolates ofKlebsiella pneumoniae and Serratiamarcescens. Infection
11:315–317. http://dx.doi.org/10.1007/BF01641355.
3. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a
clinical update. Clin Microbiol Rev 18:657–686. http://dx.doi.org/10
.1128/CMR.18.4.657-686.2005.
4. Bush K, Jacoby GA. 2010. Updated functional classification of beta-
lactamases. Antimicrob Agents Chemother 54:969–976. http://dx.doi.org
/10.1128/AAC.01009-09.
5. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibi-
tors. Clin Microbiol Rev 23:160–201. http://dx.doi.org/10.1128/CMR
.00037-09.
6. Bassetti M, Ginocchio F, Giacobbe DR, Mikulska M. 2011. Develop-
ment of antibiotics for Gram-negatives: where now? Clin Invest 1:211–
227. http://dx.doi.org/10.4155/cli.10.31.
7. Kanj SS, Kanafani ZA. 2011. Current concepts in antimicrobial therapy
against resistant Gram-negative organisms: extended-spectrum beta-
lactamase-producing Enterobacteriaceae, carbapenem-resistant Entero-
bacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. May Clin
Proc 86:250–259. http://dx.doi.org/10.4065/mcp.2010.0674.
8. Mushtaq SWM, Warner M, Ge J, Livermore DM. 2009. Activity of
cephalosporin CXA-101 (FR264205) with b-lactamase inhibitors vs. En-
terobacteriaceae, abstr F1-356, p 284. Abstr 48th Intersci Conf Antimicrob
Agents Chemother-Infect Dis Soc Am 46th Annu Mee. American Society
for Microbiology, Washington, DC.
9. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. 1993. Kinetic
interactions of tazobactam with beta-lactamases from all major structural
classes. Antimicrob Agents Chemother 37:851–858. http://dx.doi.org/10
.1128/AAC.37.4.851.
10. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. 2012.
Beta-Lactam/beta-lactam inhibitor combinations for the treatment of
bacteremia due to extended-spectrum beta-lactamase-producing Esche-
richia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:
167–174. http://dx.doi.org/10.1093/cid/cir790.
11. Titelman E, Karlsson IM, Ge Y, Giske CG. 2011. In vitro activity of
CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-
15-producing Escherichia coli andKlebsiella pneumoniae. DiagnMicrobiol
Infect Dis 70:137–141. http://dx.doi.org/10.1016/j.diagmicrobio.2011.02
.004.
12. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity
of CXA-101, a novel cephalosporin tested in combination with tazobactam
against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragi-
lis strains having various resistance phenotypes. Antimicrob Agents Che-
mother 55:2390–2394. http://dx.doi.org/10.1128/AAC.01737-10.
13. Livermore DM, Mushtaq S, Ge Y. 2010. Chequerboard titration of
cephalosporin CXA-101 (FR264205) and tazobactam versus beta-
lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 65:
1972–1974. http://dx.doi.org/10.1093/jac/dkq248.
14. Mouton J, Voss A, Arends J, Bernards S. 2007. Prevalence of ESBL in the
Netherlands: the ONE study. Int J Antimicrob Agents 29:S91–S92. http:
//dx.doi.org/10.1016/S0924-8579(07)70289-3.
15. Clinical and Laboratory Standards Institute. 2011. Performance stan-
dards for antimicrobial susceptibility testing; 21st informational supple-
Melchers et al.












ment. CLSI M100-S21. Clinical and Laboratory Standards Institute,
Wayne, PA.
16. International Organization for Standardization. 2006. Clinical labora-
tory testing and in vitro diagnostic test systems: susceptibility testing of
infectious agents and evaluation of performance of antimicrobial suscep-
tibility test devices. Part 1: referencemethod for testing the in vitro activity
of antimicrobial agents against rapidly growing aerobic bacteria involved
in infectious diseases. ISO 20776-1:2006. International Organization for
Standardization, Geneva, Switzerland.
17. EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone
diameters, version 4.0. http://www.eucast.org/clinical_breakpoints/.
18. Fass RJ, Prior RB. 1989. Comparative in vitro activities of piperacillin-
tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother
33:1268–1274. http://dx.doi.org/10.1128/AAC.33.8.1268.
19. Sader HS, Flamm RK, Streit JM, Jones RN. 2012. Activity of novel
antimicrobial ceftolozane/tazobactam tested against contemporary clini-
cal strains from USA hospitals (2011). Abstr 52nd Intersci Conf Antimi-
crob Agents Chemother. American Society for Microbiology, Washing-
ton, DC.
20. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity
of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseu-
domonas aeruginosa with various resistance patterns isolated in U.S. hos-
pitals (2011-2012). Antimicrob Agents Chemother 57:6305–6310. http:
//dx.doi.org/10.1128/AAC.01802-13.
21. Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. 2014.
Antimicrobial activity of ceftolozane/tazobactam tested against Pseu-
domonas aeruginosa and Enterobacteriaceae with various resistance pat-
terns isolated in European hospitals (2011-12). J Antimicrob Chemother
69:2713–2722. http://dx.doi.org/10.1093/jac/dku184.
22. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM,
Arlet G, Ayala J, Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L,
Woodford N. 2007. CTX-M: changing the face of ESBLs in Europe. J Anti-
microb Chemother 59:165–174. http://dx.doi.org/10.1093/jac/dkl483.
23. Bush K. 2013. Proliferation and significance of clinically relevant beta-
lactamases. AnnNYAcad Sci 1277:84–90. http://dx.doi.org/10.1111/nyas
.12023.
24. Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque
TM. 2008. Prevalence and spread of extended-spectrum beta-lactamase-
producing Enterobacteriaceae in Europe. Clin Microbiol Infect 14(Suppl
1):S144–S153. http://dx.doi.org/10.1111/j.1469-0691.2007.01850.x.
25. Hawkey PM, Jones AM. 2009. The changing epidemiology of resistance.
J Antimicrob Chemother 64(Suppl):3–10. http://dx.doi.org/10.1093/jac
/dkp256.
26. Livermore DM. 2012. Current epidemiology and growing resistance of
gram-negative pathogens. Korean J InternMed 27:128–142. http://dx.doi
.org/10.3904/kjim.2012.27.2.128.
27. Canton R, Lumb J. 2011. Emerging resistance in Gram-negative patho-
gens and implications for clinical practice. Future Microbiol 6:19–22.
http://dx.doi.org/10.2217/fmb.10.150.
MIC Proﬁle of Ceftolozane-Tazobactam Combinations




ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
